سعر إليتريكان 40 مجم 2022

Eletrikan 40 mg film-coated tablets (eletriptan), 3 tablets, Hikma Pharma, Egypt.

• Acute treatment of migraine with or without aura in adults. Not for prevention; not for cluster headache; use only after clear migraine diagnosis.Population: AdultsDailyMed / FDA

• Most common (≥5% and >placebo): asthenia, nausea, dizziness, somnolence (dose-related). Also paresthesia, flushing, chest/abdominal pressure sensations, dry mouth, etc. (see Relpax Table 1).International label, same formulation · DailyMed / FDA

• Ischemic CAD or coronary vasospasm (incl. Prinzmetal); WPW or other accessory pathway arrhythmias; history of stroke/TIA or hemiplegic/basilar migraine; peripheral vascular disease; ischemic bowel disease; uncontrolled hypertension; within 24 h of another 5-HT1 agonist or ergot-type medication; hypersensitivity to Relpax; within ≥72 h of potent CYP3A4 inhibitors (ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir).International label, same formulation · DailyMed / FDA

• Serious cardiac events possible; evaluate CV risk before use in at-risk patients. Arrhythmias; chest/throat/neck/jaw pain/pressure; cerebrovascular events; other vasospasm; medication-overuse headache; serotonin syndrome (esp. with SSRIs/SNRIs/TCAs/MAOIs); BP elevation; anaphylaxis/angioedema.International label, same formulation · DailyMed / FDA

• Ergotamine / other 5-HT1 agonistsMajorContraindicated within 24 hours — additive prolonged vasospasm risk.DailyMed / FDA
• Potent CYP3A4 inhibitorsMajorContraindicated within at least 72 hours — markedly increase eletriptan exposure.DailyMed / FDA
• SSRIs / SNRIs / TCAs / MAO inhibitorsModerateSerotonin syndrome risk with coadministration; monitor and discontinue if suspected.DailyMed / FDA

• Insufficient human data for definitive risk conclusions; animal data show developmental toxicity at clinically relevant doses. Advise patients to notify if pregnant or planning pregnancy.International label, same formulation · DailyMed / FDA
• Eletriptan is excreted in human milk. Consider maternal need vs infant risk; infant exposure can be minimised by avoiding breastfeeding for 24 hours after a dose.International label, same formulation · DailyMed / FDA

• Eletriptan: Agonist at 5-HT1B/1D receptors on intracranial vessels and trigeminal sensory nerves → cranial vasoconstriction and inhibition of pro-inflammatory neuropeptide release (US Relpax label).